C. Suppli Ulrik (Virum, Denmark), R. Louis (Liège, Belgium)
Late Breaking Abstract - Efficacy of CSJ117 on allergen-induced asthmatic responses in mild atopic asthma patients
G. Gauvreau (Hamilton, Canada), J. Hohlfeld (Hannover, Germany), L. Boulet (Laval, Canada), D. Cockcroft (Saskatoon, Canada), B. Davis (Saskatoon, Canada), J. Fitzgerald (Vancouver, Canada), S. Korn (Mainz, Germany), O. Kornmann (Frankfurt, Germany), R. Leigh (Calgary, Canada), I. Mayers (Edmonton, Canada), H. Watz (Großhansdorf, Germany), S. Grant (Cambridge, United States of America), M. Jain (Cambridge, United States of America), M. Cabanski (Cambridge, United States of America), P. Pertel (Cambridge, United States of America), I. Jones (Cambridge, United States of America), J. Lecot (Suffolk, United Kingdom), P. O'Byrne (Hamilton, Canada)
|     |
Late Breaking Abstract - Target populations for type 2 asthma biologics in a real-life population in Spain (BRAVO 2)
C. Domingo Ribas (Sabadell (Barcelona), Spain), A. Sogo Sagardia (Sabadell (Barcelona), Spain), D. Monserrate Mitchell (Sabadell (Barcelona), Spain), A. Sicras Mainar (Barcelona, Spain), A. Sicras Navarro (Barcelona, Spain), C. Engroba Teijeiro (Barcelona, Spain)
| |
Late Breaking Abstract - Cardiovascular adverse events of drugs targeting IL-5 in severe asthma: a pharmacovigilance study
J. Quinta (Toulouse, France), F. Montastruc (Toulouse, France), V. Rousseau (Toulouse, France), A. Sommet (Toulouse, France), A. Touafchia (Toulouse, France), M. Galinier (Toulouse, France), L. Guilleminault (Toulouse, France)
| |
Pharmacogenetics of inhaled corticosteroid response in adults with asthma
A. Edris (Ghent, Belgium), E. De Roos (Rotterdam, Netherlands), M. Mcgeachie (Boston, United States of America), K. Verhamme (Rotterdam, Netherlands), M. Ikram (Rotterdam, Netherlands), G. Brusselle (Ghent, Belgium), K. Tantisira (Boston, United States of America), C. Iribarren (Oakland, United States of America), M. Lu (Oakland, United States of America), A. Wu (Boston, United States of America), B. Stricker (Rotterdam, Netherlands), L. Lahousse (Ghent, Belgium)
| |
Benralizumab restored expression of key molecules involved in steroid-resistance in patients with severe asthma
K. Hirai (Shizuoka, Japan), T. Shirai (Shizuoka, Japan), T. Akamatsu (Shizuoka, Japan), S. Uehara (Shizuoka, Japan), Y. Rachi (Shizuoka, Japan), K. Tamura (Shizuoka, Japan), Y. Kishimoto (Shizuoka, Japan), M. Saigusa (Shizuoka, Japan), K. Asada (Shizuoka, Japan), K. Itoh (Shizuoka, Japan)
| |
Bronchial thermoplasty may increase steroid sensitivity by upregulating the expression of the glucocorticoid receptor
L. Zhou (Basel, Switzerland), L. Fang (Basel, Switzerland), D. Stolz (Basel, Switzerland), M. Tamm (Basel, Switzerland), M. Roth (Basel, Switzerland)
| |
Inflammatory phenotypes of asthma determine effect of inhaled corticosteroids on anti-viral immunity
M. Menzel (Lund, Sweden), J. Nieto-Fontarigo (Lund, Sweden), M. Hvidtfeldt (Copenhagen, Denmark), S. Cerps (Lund, Sweden), S. Ramu (Lund, Sweden), A. Sverrild (Copenhagen, Denmark), C. Porsbjerg (Copenhagen, Denmark), L. Uller (Lund, Sweden)
| |
The effect of inhaled corticosteroids on airway mast cells in type 2 low asthma
M. Hvidtfeldt (Copenhagen, Denmark), A. Pulga (Copenhagen, Denmark), A. Sverrild (Copenhagen, Denmark), M. Hostrup (Copenhagen, Denmark), C. Sanden (Lund, Sweden), O. Nielsen (Aarhus, Denmark), D. Bornesund (Lund, Sweden), C. Clausson (Lund, Sweden), J. Erjefält (Lund, Sweden), C. Porsbjerg (Copenhagen, Denmark)
| |
Risankizumab in severe asthma: A Phase IIa, placebo-controlled study
C. Brightling (Leicester, United Kingdom), P. Nair (Hamilton, Canada), R. Louis (Liege, Belgium), D. Singh (Manchester, United Kingdom)
| |